Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.72 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.64 |
| ▸ | BLK | P51451 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | DDX3X | O00571 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794371 | 0.92 | MGLL (0.82) | MGLLENPP2BLKBTKPOLB | |
| SCHEMBL4577453 | 0.90 | MGLL (0.65) | MGLLENPP2BLKBTKPOLB | |
| SCHEMBL3790408 | 0.87 | MGLL (0.70) | MGLLENPP2BLKBTKPOLB | |
| SCHEMBL3789318 | 0.85 | MGLL (0.85) | MGLLENPP2POLBTP53MAPT | |
| SCHEMBL3787599 | 0.85 | MGLL (0.71) | MGLLENPP2BLKBTKPOLB | |
| SCHEMBL8984657 | 0.85 | MGLL (0.76) | MGLLENPP2POLBTP53MAPT | |
| Benzyl Phenylcarbamate SCHEMBL1222943 | 0.84 | POLB (0.78) | MGLLENPP2POLBTP53MAPT | |
| SCHEMBL3780622 | 0.84 | MGLL (0.62) | MGLLENPP2BLKBTKPOLB | |
| SCHEMBL3784563 | 0.84 | MGLL (0.62) | MGLLENPP2BLKBTKPOLB | |
| SCHEMBL27498433 | 0.84 | MGLL (0.74) | MGLLENPP2POLBTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240368083-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2024-11-07 | — | — | US | disclosed |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2023-01-05 | — | — | US | disclosed |
| CN-113453681-A | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2021-09-28 | — | — | CN | disclosed |
| US-10787436-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787436-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| CN-105732636-B | Heteroaromatic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20190100511-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190100511-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2006093832-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6355810-B1 | TREATMENT AND PREVENTION OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, ATHEROSCLEROSIS | ADVANCED MEDICINE, INC. | 2002-03-12 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1083894-A1 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999063994-A9 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999063994-A1 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0651740-B1 | AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS | ZENECA LTD (GB) | 1998-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100511-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK9, CDK6 | MGLL 3798/4885ENPP2 459/4885BLK 219/4885 |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | MGLL 4467/4885ENPP2 3460/4885BLK 2177/4885 |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | MGLL 4467/4885ENPP2 3460/4885BLK 2177/4885 |
| US-20240368083-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | MGLL 4467/4885ENPP2 3460/4885BLK 2177/4885 |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | MGLL 1299/4885ENPP2 261/4885BLK 2185/4885 |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | MGLL 1026/4885ENPP2 330/4885BLK 1663/4885 |
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | MGLL 4467/4885ENPP2 3460/4885BLK 2177/4885 |
| US-10787436-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK9, CDK6 | MGLL 3798/4885ENPP2 459/4885BLK 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.